Deuterium substituted fumarate derivatives
View Patent ↗Provided herein are deuterium substituted fumarate derivatives and pharmaceutical compositions comprising deuterium substituted fumarate derivatives. Also provided is a method of treating, prophylaxis, or amelioration of a disease, comprising administering to a subject in need of treatment for the disease an effective amount of a deuterium substituted fumarate derivative or a pharmaceutical composition comprising a deuterium substituted fumarate derivative. In one embodiment, the method is a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, or Alzheimer's disease.
1. A compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein
(a) R 1 is hydrogen, deuterium, deuterated methyl, deuterated ethyl, C 1-6 aliphatic, phenyl, 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur,
(b) R 2 is —CH 2 D, —CHD 2 , or —CD 3 ,
(c) each of R 3 and R 4 , independently, is hydrogen or deuterium, wherein at least one of R 3 and R 4 is deuterium, and
(d) the compound or pharmaceutically acceptable salt has an isotopic enrichment factor for each designated deuterium atom of at least 3500.
2. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 1 is hydrogen or —CH 3 .
3. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 1 is —CD 3 .
4. The compound or pharmaceutically acceptable salt of claim 1 , wherein both of R 3 and R 4 are deuterium.
5. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 1 and R 2 are both —CD 3 , and R 3 and R 4 are both deuterium.
6. A compound or pharmaceutically acceptable salt wherein the compound is ( 2 H 6 )dimethyl fumaric(2,3- 2 H 2 ) acid ester, methyl (2-morpholino-2-oxoethyl) fumaric(2,3- 2 H 2 ) acid ester, methyl (4-morpholino-1-butyl) fumaric(2,3- 2 H 2 ) acid ester, 2-(benzoyloxy)ethyl methyl fumaric(2,3- 2 H 2 ) acid ester, 2-(benzoyloxy)ethyl ( 2 H 3 )methyl fumaric acid ester, or (S)-2-((2-amino-3-phenylpropanoyl)oxy)ethyl methyl fumaric(2,3- 2 H 2 ) acid ester, wherein the compound or pharmaceutically acceptable salt has an isotopic enrichment factor for each designated deuterium atom of at least 3500.
7. A pharmaceutical composition comprising
(a) a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein
each of R 1 and R 2 , independently, is hydrogen, deuterium, deuterated methyl, deuterated ethyl, C 1-6 aliphatic, phenyl, 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and provided that R 1 and R 2 are not hydrogen at the same time,
each of R 3 and R 4 is deuterium, and
the compound or pharmaceutically acceptable salt has an isotopic enrichment factor for each designated deuterium atom of at least 3500; and
(b) a pharmaceutically acceptable carrier or excipient.
8. The pharmaceutical composition of claim 7 , wherein R 2 is —CH 2 D, —CHD 2 , or —CD 3 .
9. The pharmaceutical composition of claim 7 , wherein R 1 and R 2 are both —CD 3 .
10. The pharmaceutical composition of claim 7 , wherein R 1 and R 2 are both —CH 3 .
11. A method of treating, or amelioration of a neurodegenerative disease, comprising administering to a human subject in need of treatment for the neurodegenerative disease an effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein
(a) each of R 1 and R 2 , independently, is hydrogen, deuterium, deuterated methyl, deuterated ethyl, C 1-6 aliphatic, phenyl, 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and provided that R 1 and R 2 are not hydrogen at the same time; and
(b) each of R 3 and R 4 , independently, is hydrogen or deuterium, wherein at least one of R 3 and R 4 is deuterium.
12. The method of claim 11 , wherein the neurodegenerative disease is selected from the group consisting of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, Alzheimer's disease, acute haemorrhagic leucoencephalomyelitis, Hurst's disease, acute disseminated encephalomyelitis, optic neuritis, spinal cord lesions, acute necrotizing myelitis, transverse myelitis, chronic progressive myelopathy, progressive multifocal leukoencephalopathy (PML), radiation myelopathy, HTLV-1 associated myelopathy, monophasic isolated demyelination, central pontine myelinolysis, and leucodystrophy, chronic inflammatory demyelinating polyneuritis (CIDP), and acute inflammatory demyelinating polyneuropathy (AIDP).
13. The method of claim 12 , which is a method of treating a neurodegenerative disease selected from the group consisting of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, and Alzheimer's disease.
14. The method of claim 13 , which is a method of treating Multiple Sclerosis.
15. The method of claim 11 , wherein the administering is orally.
16. The method of claim 15 , wherein the effective amount is administered in a single administration.
17. The method of claim 15 , wherein the effective amount is administered in separate administrations of 2, 3, 4, or 6 equal doses.
18. The method of claim 13 , wherein the administering is orally.
19. The method of claim 18 , wherein the effective amount is administered in a single administration.
20. The method of claim 18 , wherein the effective amount is administered in separate administrations of 2, 3, 4, or 6 equal doses.
21. The method of claim 18 , wherein the subject is administered a first dose for one dosing period and a second dose for a second dosing period.
22. The method of claim 11 , wherein the compound or pharmaceutically acceptable salt has an isotopic enrichment factor for each designated deuterium atom of at least 3500.
23. The method of claim 11 , wherein R 2 is —CH 2 D, —CHD 2 , or —CD 3 .
24. The method of claim 11 , wherein R 1 and R 2 are both —CD 3 , and R 3 and R 4 are both deuterium.
25. The method of claim 11 , wherein R 1 and R 2 are both —CH 3 , and R 3 and R 4 are both deuterium.
26. The method of claim 13 , wherein R 1 and R 2 are both —CD 3 , and R 3 and R 4 are both deuterium.
27. The method of claim 13 , wherein R 1 and R 2 are both —CH 3 , and R 3 and R 4 are both deuterium.
28. The method of claim 14 , wherein R 1 and R 2 are both —CD 3 , and R 3 and R 4 are both deuterium.
29. The method of claim 14 , wherein R 1 and R 2 are both —CH 3 , and R 3 and R 4 are both deuterium.